Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Aug - Newspaper Advertisement published for the 32nd Annual General Meeting is submitted.
Source: Bse
Dr Agarwals Eye Hospital Limited (DRAGARWQ)
Small CapPharma stocks · Small cap · NSE
Dr Agarwals Eye Hospital Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:50 pm ISTDetails
Quote21 Oct, 03:50 pm IST
Base fundamentals05 Oct 2026 · screener
Latest result03 Aug, 11:03 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
62BullishSMA20 -2.6% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 36
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
DRAGARWQD candles · FIT view+3.1%Latest close ₹5010.50 on 2026-10-21
Daily history is available from 2026-04-20; the requested 1Y window is partially covered.
Bar
-1.3%
RSI
36
MACD hist
-13.40
52W pos
28%
2026-10-21O ₹5077.50H ₹5100.00L ₹4900.00C ₹5010.50Vol 2,365 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
DRAGARWQNifty PharmaNifty 500
- DRAGARWQ
- -0.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +6.5 pp
Chart stats
21 Oct 2026- From 52W high
- -17.3%
- 52W range position
- 28%
- ATR (14)
- 2.7%
- Volume vs 20D
- 0.93x
- Avg traded value
- ₹1.1 Cr
- 20D price channel
- ₹4,900 - ₹5,323.5
₹6,059.7
₹4,600 - ₹6,059.7
₹135.8
Latest completed session
20-session average
13.1% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED61
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good67
Revenue +22.2% · PAT +35.3% YoY
Technical
Bullish62
Price trend and sector-relative-strength timing.
Valuation
Legacy model+28.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence77
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 67/100Rev +22% YoY · PAT +35% YoY · +19% QoQ · operating leverage · margin compression
Filed 03 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹143 Cr | +22.2% | +19.2% |
| EBITDA | ₹43 Cr | +16.2% | +26.5% |
| Operating margin | 30.0% | -200 bps | +200 bps |
| PAT | ₹23 Cr | +35.3% | +43.8% |
| PAT margin | 16.1% | +155 bps | +275 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 32.70
- P/B
- 7.20
- EV/EBITDA
- 14.24
- Market Cap
- 2493.00Cr
Profitability
- ROE
- 24.20%
- ROCE
- 17.20%
- ROA
- 9.92%
- Dividend Y
- 0.14%
Growth (CAGR)
- Revenue 5Y
- 27.00%
- EPS 5Y
- 118.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- 22.00%
Balance Sheet
- Debt/Equity
- 0.94
- Interest Coverage
- 15.10×
- Altman Z
- 5.65
- Book Value
- 717.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 7/5
- OCF
- 145.00 Cr
- EPS TTM
- 157.72
Shareholding
- Promoter Hold
- 72.67%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 38%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 143+19.2% vs prev
Net Profit
₹ CrLatest: 23.0+43.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend unclear. RSI 36.
- SMA20 falling (~2.7% over last month) — short-term momentum negative.
- RSI(14) at 36 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 17% off 52W high · 9% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
67
RS percentile
Insufficient history
1M return
-5.1%
3M return
+0.0%
6M return
+1.2%
1Y return
-
RS 1D
0
RS 20D
-
Sector rank
#1
Industry rank
#14
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
128 observations
21 Oct 2026Value 109.58-0.40%
RS vs Nifty 500110
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 61 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · UNDERVALUEDValuation8/30
Growth21/25
Quality15/20
Balance Sheet8/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
61
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
61/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 28.5%.
- Growth contributes 21/25 to the score.
Main drags
- Valuation is weaker at 8/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Balance sheet is weaker at 8/15; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
32.7
PB
7.2
EV/EBITDA
14.2
ROE
24.2%
ROCE
17.2%
FCF Yield
—
Debt/Equity
0.9
MoS
+28.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
61
Previous: 61
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+28.5%
Previous: +28.5%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
61
61
61
61
61
61
61
61
61
61
61
61
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹1,595.12
-218.3% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹7,097.4
+28.5% MoS
PEG
0.41
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INDRAMEDCO
Small
Indraprastha Medical Corporation Limited
Healthcare Services
match 165
75
15.6
27.4%
+66%
DEEP VALUE
GPTHEALTH
Small
GPT Healthcare Limited
Healthcare Services
match 162
70
29.5
28.5%
+41%
UNDERVALUED
GKSL
Small
Gujarat Kidney And Super Speciality Limited
Healthcare Services
match 162
36
94.8
11.1%
-95%
WATCHLIST
SHALBY
Small
Shalby Limited
Healthcare Services
match 161
28
36.7
2.5%
-856%
OVERVALUED
ARTEMISMED
Small
Artemis Medicare Services Limited
Healthcare Services
match 156
39
44.2
12.0%
+10%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Dr Agarwals Eye Hospital Limited operates in Hospitals, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
77Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 83rd percentile of the scored universe and 76th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
9 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
83rd percentile
overall median 67 · Pharma: 76th pctile, median 70 · Small: 86th pctile, median 66
Evidence depth
Financial-only
9 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
79
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 72.7%.
- ▸Promoter pledge is zero.
- ▸7 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Dr Agarwals Eye Hospital Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Jul - Newspaper Advertisement of the Notice of Hearing of the Company''s Petition in relation to the Scheme of Amalgamation between Dr. Agarwal''s Eye Hospital Limited and …
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 16 Jun - CRISIL reaffirmed and withdrew ratings for Rs130 crore debt facilities; ICRA continues ratings.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Jun - Joint Newspaper Advertisement of the NCLT convened meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Company, is submitted.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.